Grifols signs $90.7m respiratory deal with Aradigm

Grifols has signed a worldwide licensing agreement worth up to $90.7m to develop and commercialize Aradigm's formulations of inhaled ciprofloxacin (Pulmaquin and Lipoquin) for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE).